Esketamine versus placebo on time to remission in major depressive disorder with acute suicidality

Abstract Background Esketamine (ESK) nasal spray, taken with oral antidepressant therapy, is approved for the treatment of depressive symptoms in adults with major depressive disorder (MDD) with acute suicidal ideation or behavior. In pooled analyses of two pivotal phase 3 studies, ASPIRE I and II,...

Description complète

Détails bibliographiques

Auteurs principaux:	Dong-Jing Fu, Qiaoyi Zhang, Ling Shi, Stephane Borentain, Shien Guo, Maju Mathews, Joana Anjo, Abigail I. Nash, Marguerite O’Hara, Carla M. Canuso
Format:	Artigo
Langue:	Inglês
Publié:	BMC 2023-08-01
Collection:	BMC Psychiatry
Sujets:	Esketamine nasal spray Depressive disorder Suicidal ideation Remission Antidepressant agents
Accès en ligne:	https://doi.org/10.1186/s12888-023-05017-y
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!